Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Company Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Key Stats

• Today's Range: $0.86 to $0.90
• 50-Day Range: $0.63 to $1.20
• 52-Week Range: $0.45 to $7.20
• Volume: 45,551 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $1.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Salarius Pharmaceuticals Stock Analysis - MarketRank™

Salarius Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Salarius Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Salarius Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Salarius Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Salarius Pharmaceuticals has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.49% of the float of Salarius Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Salarius Pharmaceuticals has recently decreased by 34.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Salarius Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Salarius Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.49% of the float of Salarius Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Salarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Salarius Pharmaceuticals has recently decreased by 34.58%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for SLRX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Salarius Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Salarius Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.

SLRX Stock Analysis - Frequently Asked Questions

How have SLRX shares performed this year?

Salarius Pharmaceuticals' stock was trading at $1.84 on January 1st, 2025. Since then, SLRX shares have decreased by 51.6% and is now trading at $0.89.

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($2.40) by $1.37.

When did Salarius Pharmaceuticals' stock split?

Salarius Pharmaceuticals's stock reverse split on the morning of Monday, June 17th 2024.The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/06/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRX
• CIK: 1615219
• Web: www.salariuspharma.com
• Phone: (832) 834-6992
• Fax: N/A
• Employees: 20
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($4.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.58 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -324.13%
• Return on Assets: -174.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.01
• Quick Ratio: 1.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.95 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 2,130,000
• Free Float: 2,101,000
• Market Cap: $1.90 million
• Optionable: Not Optionable
• Beta: 0.44